Netherlands Cancer Institute, Amsterdam | Netherlands
We use function-based, genome-wide experimental strategies to develop rational combinatorial cancer treatment, targeting both cancer and immune cells. We are increasing our understanding of cancer cell network rewiring, to expose and exploit pharmacologically tractable susceptibilities. Furthermore, we are manipulating various cell types from the patient's own immune system to boost their specific cytotoxicity towards tumor cells.
Keywords: Functional oncogenomics / cancer drug target and biomarker discovery / immuno-oncology / therapy resistance / melanoma